Cutibacterium acnes

Role in diseases

Acne vulgaris

Cutibacterium acnes bacteria predominantly live deep within follicles and pores, although they are also found on the surface of healthy skin. In these follicles, C. acnes bacteria use sebum, cellular debris and metabolic byproducts from the surrounding skin tissue as their primary sources of energy and nutrients. Elevated production of sebum by hyperactive sebaceous glands (sebaceous hyperplasia) or blockage of the follicle can cause C. acnes bacteria to grow and multiply.

Cutibacterium acnes bacteria secrete many proteins, including several digestive enzymes. These enzymes are involved in the digestion of sebum and the acquisition of other nutrients. They can also destabilize the layers of cells that form the walls of the follicle. The cellular damage, metabolic byproducts and bacterial debris produced by the rapid growth of C. acnes in follicles can trigger inflammation. This inflammation can lead to the symptoms associated with some common skin disorders, such as folliculitis and acne vulgaris. Acne vulgaris is the disease most commonly associated with C. acnes infection. Cutibacterium acnes is one of the most common and universal skin diseases, affecting more than 45 million individuals in the United States. 20% of all dermatologist visits are related to treating acne-related issues. This issue often develops during hormonal periods; however, it is also apparent through early adulthood. There are no quantitative differences between C. acnes of the skin of patients with acne, but the C. acnes phylogenetic groups display distinct genetic and phenotypic characteristics. C. acnes biofilms are also found much more frequently in acne and can induce distinct immune responses to combat against acne.[[File:Comedo acne 0001.jpg|thumb|Comedo acne from C. acnes]]

Acne vulgaris is a chronic inflammatory disease of the pilosebaceous unit, which includes the hair follicle, hair shaft, and sebaceous gland and about 650 million people are affected globally by this disease. C. acnes starts to colonize on the skin around 1 to 3 years prior to puberty and grows exponentially during this time. This is why so many teens and young adults struggle with acne. Prescriptions to treat acne are often antibiotics. However, with the rise of antibiotic resistance, antibiotics are now often combined with broad-spectrum antibacterial agents such as benzoyl peroxide, and other medications like isotretinoin (commonly known by the brand name Accutane) are being used on patients with severe or resistant acne.

''Staphylococcus'' ''epidermidis''

The damage caused by C. acnes and the associated inflammation make the affected tissue more susceptible to colonization by opportunistic bacteria, such as Staphylococcus aureus. Preliminary research shows healthy pores are only colonized by C. acnes, while unhealthy ones universally include the nonpore-resident Staphylococcus epidermidis, amongst other bacterial contaminants. Whether this is a root causality, just opportunistic and a side effect, or a more complex pathological duality between C. acnes and this particular Staphylococcus species is not known. Current research has pointed to the idea that C. acnes and S. epidermidis have a symbiotic relationship. Both bacteria exist on the normal flora of the skin and a disrupt in balance of these bacteria on the skin can result in acne or other bacterial infection.

In addition to contributing to skin inflammation and acne lesions, an imbalance in these bacteria may also impair the skin's ability to heal and regenerate, leading to prolonged and more severe acne outbreaks. This disruption can also affect the skin's overall microbiome diversity, potentially increasing susceptibility to other skin conditions such as eczema or rosacea. Investigating the dynamics of this relationship may offer insights into novel therapeutic approaches for managing various skin disorders.

Ophthalmic complications

Cutibacterium acnes is a common cause of chronic endophthalmitis following cataract surgery. The pathogen may also cause corneal ulcers.

Disk herniation

Cutibacterium acnes has been found in herniated discs. The propionic acid which it secretes creates micro-fractures of the surrounding bone. These micro-fractures are sensitive and it has been found that antibiotics have been helpful in resolving this type of low back pain.

Sarcoidosis

Cutibacterium acnes can be found in bronchoalveolar lavage of approximately 70% of patients with sarcoidosis and is associated with disease activity, but it can also be found in 23% of controls. The subspecies of C. acnes that cause these infections of otherwise sterile tissues (prior to medical procedures), however, are the same subspecies found on the skin of individuals who do not have acne-prone skin, so are likely local contaminants. Moderate to severe acne vulgaris appears to be more often associated with virulent strains.

Opportunistic diseases

Cutibacterium acnes is often considered an opportunistic pathogen, causing a range of postoperative and device-related infections, notably e.g., surgical infections, post-neurosurgical infections, infected joint prostheses (especially shoulder), neurosurgical shunt infections and endocarditis in patients with prosthetic heart valves (predominantly men). C. acnes may play a role in other conditions, including SAPHO (synovitis, acne, pustulosis, hyperostosis, osteitis) syndrome, sarcoidosis and sciatica. It is also suspected a main bacterial source of neuroinflammation in Alzheimer's disease brains. It is a common contaminant in blood and cerebrospinal fluid cultures.

Antimicrobial susceptibility

Cutibacterium acnes bacteria are susceptible to a wide range of antimicrobial molecules, from both pharmaceutical and natural sources. The antibiotics most frequently used to treat acne vulgaris are erythromycin, clindamycin, doxycycline, and minocycline. Several other families of antibiotics are also active against C. acnes bacteria, including quinolones, cephalosporins, pleuromutilins, penicillins, and sulfonamides.

Antibiotic resistance

The emergence of antibiotic-resistant C. acnes bacteria represents a growing problem worldwide. The problem is especially pronounced in North America and Europe. The antibiotic families that C. acnes are most likely to acquire resistance to are the macrolides (e.g., erythromycin and azithromycin), lincosamides (e.g., clindamycin) and tetracyclines (e.g., doxycycline and minocycline).

However, C. acnes bacteria are susceptible to many types of antimicrobial chemicals found in over-the-counter antibacterial products, including benzoyl peroxide, triclosan, chloroxylenol, and chlorhexidine gluconate.

C. acnes resistance to antibiotics has increased to 64% in 2000, up from 20% in 1979. Treatments such as oral macrolides are often avoided because the bacteria has become resistant in most cases. This creates a public health issue, forcing healthcare providers to seek out other forms of treatment.

Treatments

Several naturally occurring molecules and compounds are toxic to C. acnes bacteria. Some essential oils such as rosemary, tea tree oil, clove oil, and citrus oils contain antibacterial chemicals. Natural honey has also been shown to have some antibacterial properties that may be active against C. acnes.

The elements silver, sulfur, and copper have also been demonstrated to be toxic towards many bacteria, including C. acnes.

Salicylic acid is a naturally occurring substance derived from plants (white willow bark and wintergreen leaves) used to promote exfoliation of the skin in order to treat acne. Additionally, research investigates the mechanism by which salicylic acid (SA) treats acne vulgaris. A study finds that SA suppresses the AMPK/SREBP1 (AMP-activated protein kinase)(AMPK/SREBP1 pathway is a signaling pathway involved in the regulation of lipid metabolism in sebocytes, which are the cells responsible for producing sebum in the skin) pathway in sebocytes, leading to a decrease in lipid synthesis and sebum production. SA also reduces the inflammatory response of sebocytes and decreases the proliferation of C. acnes. These results suggest that SA has a multifaceted approach in treating acne vulgaris by targeting several key factors that contribute to its development. The minimum inhibitory concentration for SA is 4000–8000 μg/mL.

Photosensitivity

Cutibacterium acnes glows orange when exposed to blacklight, possibly due to the presence of endogenous porphyrins. It is also killed by ultraviolet light. C. acnes is especially sensitive to light in the 405–420 nanometer (near the ultraviolet) range due to an endogenic porphyrin–coporphyrin III. A total radiant exposure of 320 J/cm2 inactivates this species in vitro. Its photosensitivity can be enhanced by pretreatment with aminolevulinic acid, which boosts production of this chemical, although this causes significant side effects in humans, and in practice was not significantly better than the light treatment alone.

Other habitats

Cutibacterium acnes has been found to be an endophyte of plants. Notably, grapevine appears to host an endophytic population of C. acnes that is closely related to the human-associated strains. The two lines diverged roughly 7,000 years ago, at about the same time when grapevine agriculture may have been established. This C. acnes subtype was dubbed Zappae in honour of the eccentric composer Frank Zappa, to highlight its unexpected and unconventional habitat.

References

References

1. "Genus: Cutibacterium". DSMZ.
2. (November 2016). "The natural history of cutaneous propionibacteria, and reclassification of selected species within the genus Propionibacterium to the proposed novel genera Acidipropionibacterium gen. nov., Cutibacterium gen. nov. and Pseudopropionibacterium gen. nov". International Journal of Systematic and Evolutionary Microbiology.
3. (June 2018). "Cutibacterium acnes (Propionibacterium acnes) and acne vulgaris: a brief look at the latest updates". Journal of the European Academy of Dermatology and Venereology.
4. "Genus Cutibacterium".
5. (2004-01-01). "Proprionibacterium acnes and Chronic Diseases". National Academies Press (US).
6. (October 2001). "Susceptibilities of Propionibacterium acnes ophthalmic isolates to moxifloxacin". Antimicrobial Agents and Chemotherapy.
7. (July 2004). "The complete genome sequence of Propionibacterium acnes, a commensal of human skin". Science.
8. (December 2011). "Propionibacterium acnes: infection beyond the skin". Expert Review of Anti-Infective Therapy.
9. (1900). "A bacteriological and microscopical study of over 300 vesicular and pustular lesions of the skin, with a research upon the etiology of acne vulgaris". Johns Hopkins Hospital Report.
10. (July 1946). "The Taxonomic Position of Corynebacterium acnes". Journal of Bacteriology.
11. (April 2, 2017). "Propionibacterium Cutibacterium - late breaking news and a new name".
12. (November 2018). "Cutibacterium acnes molecular typing: time to standardize the method". Clinical Microbiology and Infection.
13. (July 2018). "Cutibacterium (Formerly Propionibacterium) avidum: A Rare but Avid Agent of Prosthetic Hip Infection". The Journal of Arthroplasty.
14. (2011). "Acne and sebaceous gland function". Clinics in Dermatology.
15. (August 2010). "Proteomic identification of secreted proteins of Propionibacterium acnes". BMC Microbiology.
16. (2005). "Review of the innate immune response in acne vulgaris: activation of Toll-like receptor 2 in acne triggers inflammatory cytokine responses". Dermatology.
17. (2004). "Acne and sebaceous gland function". Clinics in Dermatology.
18. "Understanding Acne - News in Health, January 2010". Newsinhealth.nih.gov.
19. (2018). "Recent advances in understanding Propionibacterium acnes ( Cutibacterium acnes) in acne.". F1000Research.
20. (2015-09-17). "Acne vulgaris". Nature Reviews Disease Primers.
21. "Cutibacterium (Propionibacterium) Infections Clinical Presentation: History, Complications".
22. (2003). "Antibiotic-resistant acne: lessons from Europe.". British Journal of Dermatology.
23. (October 2003). "Propionibacterium acnes DNA detected in bronchoalveolar lavage cells from patients with sarcoidosis". Sarcoidosis, Vasculitis, and Diffuse Lung Diseases.
24. (November 2020). "''Staphylococcus epidermidis'' and ''Cutibacterium acnes'': Two Major Sentinels of Skin Microbiota and the Influence of Cosmetics". Microorganisms.
25. (7 August 2009). "Staphylococcus epidermidis--the 'accidental' pathogen". Nat Rev Microbiol.
26. (September 2017). "Clinical Features of Infectious Keratitis Caused by Propionibacterium Acnes". Eye & Contact Lens.
27. (2017-04-03). "Propionibacterium acnes biofilm is present in intervertebral discs of patients undergoing microdiscectomy". PLOS ONE.
28. (April 2013). "Antibiotic treatment in patients with chronic low back pain and vertebral bone edema (Modic type 1 changes): a double-blind randomized clinical controlled trial of efficacy". European Spine Journal.
29. (February 2008). "[Granulomatous diseases and pathogenic microorganism]". Kekkaku.
30. (August 2010). "Population genetic analysis of Propionibacterium acnes identifies a subpopulation and epidemic clones associated with acne". PLOS ONE.
31. Haidar R., Najjar M., Boghossian A.D., Tabbarah Z., "Propionibacterium acnes causing delayed postoperative spine infection: Review." Scandinavian Journal of Infectious Diseases. 42 (6-7) (pp 405-411), 2010
32. Nisbet, M.; Briggs, S.; Ellis-Pegler, R.; Thomas, M.; Holland, D. "Propionibacterium acnes: an under-appreciated cause of post-neurosurgical infection" [[Journal of Antimicrobial Chemotherapy]]. 60(5). NOV 2007. 1097-1103.1103.
33. (June 2008). "Propionibacterium acnes postoperative shoulder arthritis: an emerging clinical entity". Clinical Infectious Diseases.
34. (April 2009). "Infective endocarditis due to Propionibacterium species". Clinical Microbiology and Infection.
35. Perry A., Lambert P. " Propionibacterium acnes: Infection beyond the skin." Expert Review of Anti-Infective Therapy. 9 (12) (pp 1149-1156), 2011
36. (2017). "16S rRNA Next Generation Sequencing Analysis Shows Bacteria in Alzheimer's Post-Mortem Brain". Frontiers in Aging Neuroscience.
37. (2013). "Propionibacterium acnes: an underestimated pathogen in implant-associated infections". BioMed Research International.
38. (December 2017). "Cutibacterium (formerly Propionibacterium) acnes infections associated with implantable devices". Expert Review of Anti-Infective Therapy.
39. (2007-02-16). "Prescription Medications for Treating Acne". Skincarephysicians.com.
40. "The Cause Of Acne and Natural or Medical Acne Treatment".
41. (April 2007). "Guidelines of care for acne vulgaris management". Journal of the American Academy of Dermatology.
42. (September 1976). "Antimicrobiol susceptibility of Propinibacterium acnes and related microbial species". Antimicrobial Agents and Chemotherapy.
43. (January 1977). "Susceptibility of Propionibacterium acnes to seventeen antibiotics". Antimicrobial Agents and Chemotherapy.
44. (2011-07-15). "Antibiotic Susceptibility of Propionibacterium acnes". ScienceOfAcne.com.
45. (June 2011). "Treating acne with antibiotic-resistant bacterial colonization". Expert Opinion on Pharmacotherapy.
46. (February 2001). "Phenotypic and genotypic characterization of antibiotic-resistant Propionibacterium acnes isolated from acne patients attending dermatology clinics in Europe, the U.S.A., Japan and Australia". The British Journal of Dermatology.
47. (March 2003). "Antibiotic-resistant acne: lessons from Europe". The British Journal of Dermatology.
48. (May 2002). "Prevalence of antibiotic-resistant propionibacteria on the skin of acne patients: 10-year surveillance data and snapshot distribution study". The British Journal of Dermatology.
49. (December 2008). "Antibiotic-resistant Propionibacterium acnes suppressed by a benzoyl peroxide cleanser 6%". Cutis.
50. (December 19, 2017). "Q&A for Health Care Professionals: Health Care Antiseptics".
51. (July 1, 2004). "Vanity, Vitality, and Virility: The Chemistry Behind the Products You Love to Buy". Oxford University.
52. (July 2012). "Efficacy of chlorhexidine gluconate ointment (Oronine H(®)) for experimentally-induced comedones". Clinical, Cosmetic and Investigational Dermatology.
53. (October 2007). "Investigation of antibacterial activity of rosemary essential oil against Propionibacterium acnes with atomic force microscopy". Planta Medica.
54. (October 1995). "Antimicrobial effects of tea-tree oil and its major components on Staphylococcus aureus, Staph. epidermidis and Propionibacterium acnes". Letters in Applied Microbiology.
55. (January 2009). "The antibacterial activity of clove essential oil against Propionibacterium acnes and its mechanism of action". Archives of Dermatology.
56. (January 2012). "A review on recent research results (2008–2010) on essential oils as antimicrobials and antifungals. A review.". Flavour and Fragrance Journal.
57. (January 2008). "Chemical composition and biological activities of essential oils extracted from Korean endemic citrus species". Journal of Microbiology and Biotechnology.
58. (October 2006). "Effect of antibacterial honey on the ocular flora in tear deficiency and meibomian gland disease". Cornea.
59. (February 2010). "In vitro antimicrobial activity of silver-processed catheters for neurosurgery". The Journal of Antimicrobial Chemotherapy.
60. (1953). "Antibacterial effect of elemental sulfur". The Journal of Infectious Diseases.
61. (September 1993). "Antibacterial activity of multilayer silver-copper surface films on catheter material". Canadian Journal of Microbiology.
62. (October 2019). "Salicylic acid treats acne vulgaris by suppressing AMPK/SREBP1 pathway in sebocytes". Experimental Dermatology.
63. (October 2019). "''In vitro'' Antimicrobial Activity of Acne Drugs Against Skin-Associated Bacteria". Scientific Reports.
64. (May 2000). "Phototherapy with blue (415 nm) and red (660 nm) light in the treatment of acne vulgaris". The British Journal of Dermatology.
65. (February 2009). "Short and limited effect of long-pulsed dye laser alone and in combination with photodynamic therapy for inflammatory rosacea". Journal of the European Academy of Dermatology and Venereology.
66. (May 2014). "Current evidence and applications of photodynamic therapy in dermatology". Clinical, Cosmetic and Investigational Dermatology.
67. (May 2014). "Interkingdom transfer of the acne-causing agent, Propionibacterium acnes, from human to grapevine". Molecular Biology and Evolution.